Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Adakveo®
( crizanlizumab )OncologyAdvanced Accelerator Applications -
Afinitor Disperz®/Votubia®
( everolimus )
Oncology -
Afinitor®/Votubia®
( everolimus )Oncology -
Aimovig®
( erenumab )Neuroscience -
Alomide
Available in -
Arzerra®
( ofatumumab )OncologyAvailable in -
Beovu®
( brolucizumab )Ophthalmology -
Betoptic S®
Available in -
Ciprodex®
( ciprofloxacin, dexamethasone )OphthalmologyAvailable in